RxDoctor Payments Data

Jennifer Hutchinson

Primary Care · West Union, IANPI 1538699806

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AbbVie at 31.4% of the total. Reporting peaked in 2023 at $248 and has fallen 61.7% since, to $95 in 2025.

$664in general payments, 2019–2025

Across 15 payments — averaging $44.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$208
  • AstraZeneca$156
  • Teva Pharmaceuticals USA, Inc.$86
  • Amgen$49
  • Insulet Corporation$45
  • Abbott$40
  • plus $78 from 3 others

What the payments were for

  • Food & beverage$664100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$664 in reported general payments places this provider in the 70th percentile of 36 primary care providers in Iowa.

See all primary care providers in Iowa

Medicare billing

Part B allowed, 2024
$86,847
Medicare patients
215
Services billed
1,275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin92$107,344
TrulicityDulaglutide75$98,086
FarxigaDapagliflozin Propanediol62$72,364
OzempicSemaglutide62$68,914
EliquisApixaban59$48,491
MounjaroTirzepatide37$41,050
WegovySemaglutide19$25,774
RybelsusSemaglutide16$24,255
MyrbetriqMirabegron28$20,850
XareltoRivaroxaban20$20,368
Tresiba Flextouch U-200Insulin Degludec17$16,404
Breo ElliptaFluticasone/Vilanterol26$13,285
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$12,241
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$10,376
Incruse ElliptaUmeclidinium Bromide28$9,421

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$156$76,26277 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 36 primary care providers in Iowa.

Other primary care in West Union

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →